539-P: Evaluation of a Comprehensive Physical Fitness Index to Predict Future Prediabetes and Metabolic Syndrome (MetS)

• Published in: Diabetes (New York, N.Y.) Vol. 71; no. Supplement_1
• Main Authors: SATO, TAKAAKI, FUJIHARA, KAZUYA, YAMADA, MAYUKO H., CHO, KAORI, YAGUCHI, YUTA, YAMAMOTO, MASAHIKO, KITAZAWA, MASARU, ISHIGURO, HAJIME, OSAWA, TAEKO, YAMADA, TAKAHO, KATO, KIMINORI, SONE, HIROHITO
• Format: Journal Article
• Language: English
• Published: New York American Diabetes Association 01.06.2022
• Subjects: Arteriosclerosis; Diabetes; Diabetes mellitus (non-insulin dependent); Metabolic syndrome; Metabolism; Muscle strength; Physical fitness; Principal components analysis
• DOI: 10.2337/db22-539-P
• ISSN: 0012-1797

Muscle strength, balance, and flexibility has been associated with the development of type 2 diabetes and atherosclerosis, but little is known whether the physical score (PS) , which integrates these physical fitness indices, can predict future metabolic diseases. We investigated the longitudinal relationship between baseline and changes in PS and future prediabetes and MetS. Analyzed were 5620 men aged 30 to 69 y without MetS who underwent physical fitness tests. Principal component analysis was performed on the correlation matrix of the physical fitness test results according to age. PS was defined as the first principal component score. Associations between PS values at the start of observation (year 0) , change in the PS one year later (year 1) and the onset of prediabetes and MetS at the end of observation (years 4 or 5) were examined by Cox hazard regression analysis. The same analysis was performed for the 3812 men without prediabetes at baseline. No significant difference was found for the development of prediabetes, but a significant difference was found for development of MetS. The hazard ratio for the development of MetS was 1.30 (1.18,1.44) for every 1 decrease in the PS in year 0 and 1.35 (1.13,1.60) for every 1 decrease in the change in PS from year 0 to year 1. PS was a simple and non-invasive indicator to predict MetS. Disclosure T. Sato: None. K. Fujihara: None. M. Yamamoto: None. M. Kitazawa: None. H. Ishiguro: None. T. Osawa: None. H. Sone: Research Support; Astellas Pharma Inc., Eisai Co., Ltd., Kyowa Kirin Co., Ltd., Novo Nordisk, Ono Pharmaceutical Co., Ltd., Taisho Pharmaceutical Holdings Co., Ltd., Takeda Pharmaceutical Company Limited.